Physician profile
Kunal Dalal
NPI 1497065338
$4,911.02
in general payments reported to CMS, 2019-2025
37 companies · $370 in 2025
The $370 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $343 · 2021: $252 · 2022: $1,196 · 2023: $1,082 · 2024: $979 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,408.58 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,352.94 | 2019-2025 | Skyrizi, Mavyret, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $370.98 | 2019-2022 | |
| Pfizer INC. | $247.04 | 2019-2025 | |
| Janssen Biotech, INC. | $223.02 | 2019-2024 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $180.81 | 2019-2024 | Entyvio, Eohilia |
| Ferring Pharmaceuticals INC. | $179.86 | 2020-2023 | Rebyota |
| Gilead Sciences, INC. | $131.88 | 2019-2023 | |
| Boston Scientific Corporation | $127.36 | 2023-2024 | Axios, Exalt Model D |
| Merck Sharp & Dohme LLC | $123.26 | 2022-2024 | Dificid |
| Genzyme Corporation | $117.14 | 2024 | |
| Romark Laboratories, Lc | $104.09 | 2020 | |
| Celgene Corporation | $97.72 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $67.98 | 2022-2024 | Dupixent |
| Ardelyx, INC. | $53.60 | 2023-2025 | Ibsrela |
| Pentax of America, INC. | $46.65 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $40.06 | 2022-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Daiichi Sankyo INC. | $38.42 | 2022-2023 | Injectafer |
| Lilly USA, LLC | $34.87 | 2024 | Omvoh |
| Nestle Healthcare Nutrition INC. | $33.57 | 2022-2023 | |
| Capsovision, INC. | $31.89 | 2024 | Capsocam Plus |
| Intercept Pharmaceuticals, INC. | $31.55 | 2020-2024 | |
| Alnylam Pharmaceuticals INC. | $27.21 | 2022 | |
| Janssen Pharmaceuticals, INC | $27.09 | 2019 | |
| Ironwood Pharmaceuticals, INC | $26.44 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $23.07 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $20.32 | 2025 | Vowst |
| Qol Medical, LLC | $17.19 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $16.89 | 2022 | |
| Celltrion USA INC. | $16.59 | 2025 | Vegzelma |
| Orphalan INC | $16.31 | 2025 | Cuvrior |
| Fresenius Kabi USA, LLC | $15.84 | 2023 | Idacio |
| Amgen INC. | $15.14 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.11 | 2023 | Cyltezo |
| Corcept Therapeutics | $14.64 | 2022 | |
| Ambu INC. | $13.20 | 2021 | |
| Alfasigma USA, INC. | $11.29 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunal Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.